ORIGINAL ARTICLE businesswire.ca May 11, 2021
Breakthrough technology evaluates cognitive function when a brain disorder such as injury, dementia or neurological impacts of COVID-19 are suspected
HAMILTON, Ontario–(BUSINESS WIRE)–VoxNeuro announces the release of their software as a medical device, the Cognitive Health Assessment Management Platform™ (CHAMP), as they pave their way to the US market. With successful registration with the FDA as a Medical Device Establishment for the distribution of the CHAMP software, a Class II Exempt Medical Device, VoxNeuro is on plan to globally change the way brain health is managed and treated.
CHAMP works in tandem with VoxNeuro’s Cognitive Health AssessmentTM to proactively track cognitive health throughout aging, and to evaluate cognitive function when a brain disorder or symptoms related to cognitive dysfunction are suspected.
To continue reading this article CLICK HERE
